Deals channel feed

Lil­ly, In­cyte-al­lied Chi­nese drug­mak­er In­novent bags Roche as part­ner in deal that could yield bil­lions

5 years ago
China
Cell/Gene Tx

When times got tough, the bio­phar­ma in­dus­try hit the Zoom but­ton and kept things mov­ing at a multi­bil­lion-dol­lar clip

5 years ago

Months af­ter steer­ing a seizure res­cue ther­a­py to mar­ket, UCB bags an­oth­er promis­ing late-stage as­set for $125M up­front

5 years ago

Does As­traZeneca CEO Pas­cal So­ri­ot re­al­ly want to merge with Gilead? A Bloomberg sto­ry sug­gests he was in­ter­est­ed — but it's hard to see why

5 years ago

Por­tion of Neil Wood­ford’s re­main­ing in­vest­ments, in­clud­ing Nanopore, sold off for $284 mil­lion

5 years ago
Financing

Bris­tol My­ers is clean­ing up the post-Cel­gene merg­er pipeline, and they’re sweep­ing out an ex­per­i­men­tal check­point in the process

5 years ago

José Basel­ga finds promise in new class of RNA-mod­i­fy­ing can­cer tar­gets, lock­ing in 3 pre­clin­i­cal pro­grams with $55M

5 years ago

Once a high fly­er, a stag­ger­ing Aduro is auc­tion­ing off most of the pipeline as CEO Stephen Isaacs hands off the shell to new own­ers

5 years ago
People

Eyes on he­mo­phil­ia prize, Re­gen­eron adds a $100M wa­ger on joint de­vel­op­ment cam­paign with In­tel­lia

5 years ago
R&D

Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

5 years ago

In lat­est can­cer deal, Bris­tol My­ers Squib­b's new BD chief bets $65M in search for more tar­gets like PARP

5 years ago

PhII Alzheimer's da­ta loom­ing, Sh­iono­gi spend­ing up to $500M on a buy­out in­volv­ing one of the tough­est bets in biotech

5 years ago

Af­ter de­cou­pling from Re­gen­eron, Sanofi says it’s time to sell the $13B stake picked up in the mar­riage

5 years ago
R&D

Roche beefs up di­ag­nos­tic arm with an­oth­er bet on faster, cheap­er DNA se­quenc­ing

5 years ago

George Church spin­off swal­lows a key man­u­fac­tur­ing part­ner as it preps CRISPR-edit­ed pig or­gans for an­i­mal test­ing

5 years ago

BAR­DA of­fers a tiny start­up up to $812M to cre­ate a US-based drug man­u­fac­tur­er — and the CEO comes with a price goug­ing con­tro­ver­sy on his ré­sumé

5 years ago
Startups
Bioregnum

Roche’s James Sabry ze­roes in on a new path­way for pro­tein degra­da­tion — and he’s pay­ing $135M cash for a hot tick­et

5 years ago

Oblit­er­at­ed by Alzheimer's fail­ure, Neu­rotrope re­lin­quish­es its Nas­daq spot in re­verse merg­er

5 years ago

Look­ing for first-in-class glo­ry, Boehringer In­gel­heim ac­quires two pre­clin­i­cal can­cer drugs from Ver­sant-backed biotech

5 years ago

How the pan­dem­ic helped se­cure a rare can­cer drug for Menar­i­ni

5 years ago

Boehringer In­gel­heim sharp­ens reti­nal strat­e­gy, scoop­ing up dry AMD drug from a Swiss team be­hind No­var­tis' Beovu

6 years ago

Mer­ck dou­bles down on Sky­hawk's tech to drug RNA, promis­ing $600M per au­toim­mune, meta­bol­ic tar­get

6 years ago

Blue­bird takes $200M pay­out from Bris­tol My­ers as Covid-19, BLA de­lays force ex­ecs to bring out the bud­get ax

6 years ago
FDA+

Spun out of George Church's lab, this biotech up­start is map­ping the AAV uni­verse for No­var­tis, Sarep­ta to gaze

6 years ago
Startups
Cell/Gene Tx
First page Previous page 90919293949596 Next page Last page
A service from the Financial Times